How to choose Oxygen Delivery Systems

From bedside cannulas to bulk liquid tanks — what procurement teams need to understand before specifying, sourcing, or expanding hospital oxygen infrastructure.

---

What this is and who buys it

Oxygen delivery systems is not a single product category — it is a layered ecosystem ranging from sub-$5 disposable nasal cannulas to multi-million-dollar piped medical gas networks. At the bedside terminal level, you are choosing between nasal cannulas, simple masks, Venturi masks, non-rebreather masks, and high-flow nasal cannula (HFNC) therapy units. At the facility supply level, decisions involve bulk liquid oxygen (LOX) vacuum-insulated evaporators (VIEs), pressure-swing adsorption (PSA) generators, manifolded cylinder banks, and the piping distribution system that connects supply to every outlet in the building. These decisions are not independent: a miscalculated PSA plant or an undersized LOX evaporator will cause pressure failures at the point of care when HFNC units run simultaneously.

The buying team for oxygen systems typically spans several departments. Hospital procurement handles vendor contracts and capital authorization. Biomedical engineering evaluates device-level compliance and leads acceptance testing. Facilities or plant operations owns the bulk supply infrastructure and interfaces with the medical gas installer. Respiratory therapy and anesthesia leads define clinical demand — particularly for HFNC and anesthesia workstation gas inputs. ASC administrators, dental office owners, and clinic managers are increasingly involved as NFPA 99 expands its scope to alternate care sites [S3].

Purchase triggers vary widely. Post-COVID surge planning exposed how quickly cylinder banks deplete under simultaneous HFNC use. NFPA 99 risk-category upgrades during renovation require infrastructure reclassification. Equipment reaching end-of-life — particularly aging PSA sieve beds or concentrators beyond their 4–7 year average service window — forces capital replacement decisions. New construction triggers full system design from scratch. In all of these scenarios, the cost of getting the supply-demand match wrong is clinical, not just financial.

---

Key decision factors

Match the source to demand and risk category. The most practical guidance from industry references is that PSA generation is typically better suited as the primary source for facilities under 600 beds, with LOX as backup, while LOX bulk tanks scale more effectively for higher-consumption facilities above that threshold with PSA as backup [S5]. LOX VIE tanks hold 500–25,000 liquid liters and can deliver vaporizer flow output ranging from roughly 150 to 20,000 L/min, while PSA systems are rated by Nm³/h capacity that must be sized against your simultaneous peak demand, not your average.

Plan for three-tier supply redundancy. NFPA 99-aligned design requires a primary source, a secondary source that activates automatically on primary failure, and a reserve emergency source [S3, S4]. Bulk cryogenic LOX is classified as Category 1 wherever supply failure is immediately life-threatening, which means daily verification of source pressure, liquid level, vaporizer function, and primary/secondary changeover — not monthly or quarterly [S13]. Redundancy is not optional in these environments; it is a code requirement with documented inspection obligations.

Size for peak HFNC load, not average flow. High-flow nasal cannula therapy draws up to 60–70 L/min per patient [S6]. Running even four HFNC units simultaneously in an ICU or ED represents a combined demand that can exceed cylinder manifold capacity rapidly, cause evaporator freeze-up on liquid oxygen systems, or trigger pressure drops through undersized piped distribution. HFNC should not be routinely run on cylinder manifolds unless the manifold pool and changeover frequency have been explicitly calculated for that load.

Verify FiO₂ accuracy across the device class you're buying. Not all oxygen delivery devices are interchangeable at the point of care. Standard nasal cannulas deliver 24–44% FiO₂ at 1–6 L/min; simple face masks reach 35–60% FiO₂ at 5–10 L/min but without precision; Venturi masks use color-coded fixed-orifice valves to deliver a specific FiO₂ (24–60%) independent of patient breathing pattern; non-rebreathers provide greater than 90% FiO₂ for acute hypoxia [S8]. Specifying the wrong device class for a clinical setting is a safety issue, not just a cost issue.

Confirm electrical and gas-input compatibility. Devices that accept 50 psi / 4 bar gas intake typically incorporate internal bronze sintered filters to protect internal components from contaminated gas sources. Before procuring HFNC blenders or anesthesia workstations, verify NEMA receptacle type, isolated power panel requirements, and whether transport battery operation is supported. Mismatched power infrastructure discovered post-delivery is a common and avoidable delay.

Humidification thresholds drive accessory spend. A humidifier is required for continuous oxygen flows above 4 L/min [S8], and disposable humidifier bottles are not recommended above 6 L/min due to back-pressure limitations. This matters for budget planning: HFNC systems require heated humidification circuits that are typically disposable per patient, and annual consumable spend on circuits and water chambers can exceed the capital cost of the device within two to three years.

PSA output quality is maintenance-dependent. Unlike LOX, which delivers a chemically consistent product, PSA plants generate oxygen through molecular sieve separation, and sieve-bed degradation over time can silently reduce output concentration. Poorly maintained PSA plants have been documented delivering concentrations substantially below the 90% minimum threshold [S5, S9]. Continuous inline oxygen purity monitoring with an alarm tied to the master alarm panel is not optional — it is the only way to catch this failure mode before it reaches the patient.

Monitor and alarm architecture. NFPA 99 requires annual reviews of bulk oxygen system capacity, full annual inspection of central supply systems including major components, and periodic inspection of all warning systems and alarms [S13]. When scoping a purchase or upgrade, verify that every zone valve, area alarm panel, and master alarm point is included in the maintenance program scope — these are frequently the items that expire or fall out of maintenance programs as facilities age.

---

What it costs

Oxygen system pricing spans five orders of magnitude depending on whether you're buying a box of nasal cannulas or commissioning a PSA plant. Public list pricing for hospital-grade infrastructure is rarely published; the figures below are derived from procurement disclosures and industry references, and capital infrastructure will always require a direct quote.

• Entry-level consumables and bedside terminals ($15–$500 per unit): Disposable nasal cannulas run approximately $1–$5 each; simple, Venturi, and non-rebreather masks $3–$25. Adult high-flow oxygen nasal cannulas are approximately $22 per disposable set. A standard J-size cylinder (6,800 L) costs roughly $60–$250, excluding regulator, flowmeter, and ongoing refill costs of $25–$100 per fill.
• Mid-range device and zone infrastructure ($1,500–$25,000 per unit): Portable oxygen concentrators typically run $1,500–$4,000; stationary 5–10 L/min concentrators $800–$2,500. HFNC therapy units — including heated humidifier-blender combinations — commonly fall in the $3,000–$12,000 range. Manifold panels, zone valves, and area alarm panels typically run $2,000–$15,000 per zone.
• Facility infrastructure ($50,000 to seven figures): PSA medical oxygen plants range from roughly $50,000 for small-capacity systems to $500,000+ for large hospital configurations. LOX VIE installation and infrastructure ranges from $10,000 to several hundred thousand dollars, with ongoing annual costs that can reach approximately 40% of initial capital. Full piped medical gas distribution for a new hospital wing routinely runs into seven figures.

---

Common use cases

Oxygen systems are specified across a wider range of settings than most procurement teams initially anticipate, and each environment has meaningfully different demand profiles and compliance obligations.

• Operating rooms and ICUs: These are NFPA 99 Category 1 environments where supply failure is immediately life-threatening. Medical oxygen, medical air, and anesthesia vacuum must operate under maximum-frequency inspection and maintenance programs [S3, S13].
• Emergency departments and acute respiratory failure wards: HFNC systems delivering up to 60 L/min of heated, humidified oxygen are now standard-of-care for COVID-19 and other hypoxic respiratory failure presentations. Surge capacity planning must account for simultaneous multi-patient HFNC use [S6, S7].
• General wards and step-down units: Wall-outlet flowmeters with low-flow nasal cannulas serve stable patients requiring supplemental oxygen at 1–6 L/min. Nasal cannulas remain the most commonly used oxygen delivery device across inpatient environments [S8].
• Ambulatory surgery centers, dental offices, and clinics: NFPA 99 applies to these settings [S3]; E-cylinder emergency kits with regulators are standard, with the primary supply often being a small manifold or concentrator rather than a bulk LOX system.

---

Regulatory and compliance

Most oxygen delivery devices are FDA Class II under 21 CFR Part 868 (Anesthesiology Devices) and require premarket notification (510(k)) clearance [S2]. HFNC humidified oxygen delivery devices were formally classified into Class II with special controls in 2018 [S1]. Oxygen gas analyzers fall under 21 CFR 868.1720, product code CCL. When reviewing vendor submissions, ask for 510(k) clearance numbers and confirm that the specific model number — not just the product family — is cleared. Devices are typically tested to IEC 60601-1 for electrical safety and IEC 60601-1-2 for electromagnetic compatibility; oxygen sensor performance references ISO 80601-2-55:2018, and pulse oximetry components follow ISO 80601-2-61 [S10, S11].

NFPA 99 is the dominant facility-level compliance framework in the United States. It mandates risk categorization (Categories 1–4), bulk system design standards, three-tier redundancy, alarm hierarchy, and inspection cadence [S3, S4]. Notably, the 2018 edition added explicit permission for oxygen concentrators as central piped-gas supply sources — a significant change for facilities considering PSA-based infrastructure [S3]. The Joint Commission standard EC.02.05.09 and CMS Conditions of Participation require that piped medical gas systems operate under a traceable maintenance program with documented daily logs, quarterly functional tests, and annual performance qualifications. PSA-produced oxygen (93% O₂) and USP Oxygen (≥99%) are separate pharmacopeial monographs — confirm which monograph your generator's output satisfies before purchasing.

---

Service, training, and total cost of ownership

Bulk LOX, PSA, and piped distribution systems must be installed by ASSE 6010-certified medical gas installers, followed by independent third-party verification to ASSE 6030 and authority-having-jurisdiction (AHJ) sign-off before commissioning. Passive VIE systems require a power source for the pump during cryogenic deliveries, which is sometimes supplied by the delivery truck's diesel generator — a logistical dependency worth understanding if your facility has limited electrical infrastructure at the tank pad.

Training obligations extend across multiple staff groups. Respiratory therapists and nurses need documented competency in HFNC setup and alarm response. Facilities and biomed staff need training on manifold changeover procedures and Emergency Oxygen Supply Connection (EOSC) operation, which NFPA 99 now requires to include master alarm connection points for temporary supply monitoring [S3]. These competency records are reviewed during Joint Commission surveys and CMS inspections.

Calibration and PM schedules are not optional and not trivial. Galvanic oxygen sensors in analyzers and concentrators typically have a 1–2 year service life and require periodic two-point calibration. Pressure regulators and zone valves need annual inspection. Manufacturers typically recommend quarterly CO monitor calibration even where code minimum is annual [S13]. For sieve-bed concentrators, confirm replacement intervals in writing — this is often the single largest maintenance cost over the device lifecycle. Annual full-service contracts for LOX or PSA infrastructure typically run 8–15% of capital cost; OEM service agreements for HFNC units commonly run $400–$1,200 per unit per year. When negotiating, push for explicit uptime SLAs, particularly for Category 1 systems — a 4-hour onsite response commitment is a reasonable minimum benchmark. LOX VIE tanks, when maintained and recertified on schedule, can remain in service 20–30 years; well-maintained oxygen concentrators average 4–7 years [S5].

---

Red flags to watch for

Sole reliance on cylinder manifolds for HFNC therapy is a recurring and serious procurement error. At 60–70 L/min per patient, cylinders deplete rapidly and simultaneous multi-patient use can collapse system pressure within hours — this configuration is not appropriate for primary HFNC supply without a large manifold pool and a very high changeover frequency [S6].

PSA plants quoted without continuous inline oxygen purity monitoring should be treated with skepticism. A purity analyzer with an alarm tied to the master panel is the only reliable safeguard against concentration drift from sieve-bed degradation; buying a PSA plant without one is analogous to buying an anesthesia machine without a gas monitor [S5, S9].

Be cautious when vendors cite "NFPA 99 compliance" without specifying an edition year. Your AHJ may be enforcing the 2012, 2018, 2021, or 2024 edition, and the differences — particularly around oxygen concentrators as central supply and EOSC master alarm requirements — are substantive [S3]. Ask specifically.

Finally, watch the consumable cost structure on HFNC units before committing to a capital purchase. Disposable patient circuits, water chambers, and cannulas are proprietary to most HFNC platforms, and annual consumable spend routinely exceeds the device's purchase price within two to three years of deployment. Model this in your TCO analysis before the purchase order is signed.

---

Questions to ask vendors

1. Which NFPA 99 edition (2012, 2018, 2021, or 2024) does your design comply with, and which risk categories (1–4) is the system rated for?
2. Provide FDA 510(k) clearance numbers, product codes, and applicable IEC 60601-1, ISO 80601-2-xx, and ISO 14971 test reports for every device in the quote.
3. For PSA or LOX sources: what is the guaranteed minimum O₂ concentration at maximum simultaneous-use load including peak HFNC and ventilator demand, and how is purity continuously monitored and alarmed?
4. What is your guaranteed onsite response time for Category 1 system failures, and what loaner or temporary supply provisions are included in the service contract?
5. Itemize 5-year total cost of ownership: capital, installation and commissioning, consumables (circuits, sieve beds, filters), preventive maintenance, calibration, and energy cost in kWh/m³ for PSA systems.
6. Will you provide ASSE 6030 third-party verification documentation and complete as-built drawings — including zone valve maps — before final acceptance sign-off?

---

Alternatives

The lease-versus-own decision is especially consequential for bulk supply infrastructure. LOX bulk tanks are almost universally leased from the gas supplier, with the supplier owning and maintaining the VIE — this eliminates capital outlay and major maintenance responsibility but locks the facility into long-term gas pricing with limited leverage at renewal. PSA generators, by contrast, are typically purchased outright to escape per-Nm³ pricing; they require reliable power and disciplined maintenance but offer the lowest long-term operational cost and supply autonomy for most mid-sized hospitals [S5].

For device-level capital, refurbished concentrators and HFNC units can reduce upfront cost by 30–50%, but this comes with meaningful risk unless the seller documents sieve-bed replacement, compressor service history, and FiO₂ verification across all flow settings. Refurbished equipment is defensible for surge or backup inventory; it is harder to justify as primary Category 1 supply. New units carry OEM warranties (typically 2–3 years) and current 510(k) labeling that simplifies Joint Commission documentation. For facilities weighing in-house biomed service against OEM or third-party contracts, a hybrid model is common: OEM contracts for PSA/LOX systems where software and parts priority matter most, in-house staffing for terminal devices and zone hardware where response time and institutional knowledge are the primary value. Finally, for portable applications such as patient transport or hospital-at-home programs, pulse-dose oxygen-conserving devices offer longer cylinder runtime, but should not be used at flows above 4 L/min where continuous-flow delivery is clinically indicated [S8].

---

Sources

• FDA — Federal Register: Classification of the High Flow Humidified Oxygen Delivery Device (Class II)
• eCFR — 21 CFR Part 868 Anesthesiology Devices
• NFPA 99 Health Care Facilities Code — Medical Gas Requirements (CHT Healthcare overview)
• Compass Cryogenics — Medical Gas Risk Assessment & NFPA 99 Categories 1–4
• Open Critical Care — Overview of Oxygen Sources (LOX, PSA, cylinders)
• Open Critical Care — Oxygen Delivery Devices FAQ (HFNC supply considerations)
• Gomez-Restrepo et al., Cost Analysis of HFOT vs Conventional Oxygen Therapy in COVID-19 (PMC)
• Diaz et al., Oxygen Devices and Delivery Systems (Breathe / NIH PMC)
• Chatburn RL & Branson RD — Shortages and Vulnerabilities of Hospital Oxygen Systems, Respir Care 2022
• FDA 510(k) Summary K102245 — Oxygen Concentrator
• FDA Guidance — Pulse Oximeters Premarket Notification (ISO 80601-2-61)
• HFM Magazine — Medical Gas Storage Room Compliance (IBC/IFC limits)
• OxMaint — Hospital Medical Gas System Maintenance & NFPA 99 Chapter 14